Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | APEX1 | P27695 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509671 | 0.91 | ALDH1A1 (0.46) | AKR1B1CYP1A2CYP2C19POLBALDH1A1 | |
| SCHEMBL70565 | 0.89 | AKR1B1 (0.71) | AKR1B1CYP1A2CYP2C19GAAKDM4E | |
| Hydrochloric Acid SCHEMBL8922940 | 0.87 | AKR1B1 (0.68) | AKR1B1CYP1A2CYP2C19GAAKDM4E | |
| SCHEMBL13438518 | 0.87 | AKR1B1 (0.48) | AKR1B1GAAKDM4EMAPTHPGD | |
| SCHEMBL13554933 | 0.83 | ENPP2 (0.44) | TSHRPOLBALDH1A1SLC7A5 | |
| SCHEMBL13905068 | 0.83 | BCL2 (0.47) | CYP1A2CYP2C19GAAMAPTHPGD | |
| SCHEMBL1515871 | 0.83 | AKR1B1 (0.58) | AKR1B1CYP1A2CYP2C19GAAKDM4E | |
| SCHEMBL4402323 | 0.83 | AKR1B1 (0.62) | AKR1B1CYP1A2CYP2C19GAAKDM4E | |
| Acetic Acid SCHEMBL9783357 | 0.82 | AKR1B1 (0.57) | AKR1B1CYP1A2CYP2C19GAAKDM4E | |
| SCHEMBL8277240 | 0.82 | CA2 (0.62) | AKR1B1GAAKDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2021-01-28 | — | — | US | disclosed |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2020-05-28 | — | — | US | disclosed |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | THERAVANCE RESPIRATORY COMPANY, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | THERAVANCE RESPIRATORY COMPANY, LLC | 2019-10-03 | — | — | US | disclosed |
| US-20050222128-A1 | Compounds for the treatment of diseases | PFIZER INC | 2005-10-06 | — | — | US | disclosed |
| WO-2005092840-A1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005092887-A1 | COMPOUNDS FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-10-06 | — | — | WO | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
| WO-2005080324-A1 | SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| WO-2004108676-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| EP-1477167-A1 | [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists | Pfizer Limited (GB) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300504-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | AKR1B1 334/4885CYP1A2 686/4885CYP2C19 1597/4885 |
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | AKR1B1 3894/4885CYP1A2 2291/4885CYP2C19 852/4885 |
| US-10836744-B2 | Diamide compounds having muscarinic receptor antagonist and β2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2A | AKR1B1 413/4885CYP1A2 718/4885CYP2C19 1537/4885 |
| US-20050014763-A1 | 2-Amino-pyridine derivatives useful for the treatment of diseases | PAH, AADAT, IL4I1 | AKR1B1 256/4885CYP1A2 26/4885CYP2C19 130/4885 |
| US-20210024493-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | AKR1B1 364/4885CYP1A2 475/4885CYP2C19 1234/4885 |
| US-10590107-B2 | Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity | ADRB2, ADRB1, ADRA2B | AKR1B1 334/4885CYP1A2 686/4885CYP2C19 1597/4885 |
| US-20230190950-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | AKR1B1 4500/4885CYP1A2 4779/4885CYP2C19 3097/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | AKR1B1 3894/4885CYP1A2 2291/4885CYP2C19 852/4885 |
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | AKR1B1 4500/4885CYP1A2 4779/4885CYP2C19 3097/4885 |
| US-20230287365-A1 | COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION | ENTPD1, ENTPD2, ENTPD5 | AKR1B1 1773/4885CYP1A2 3232/4885CYP2C19 3696/4885 |
| US-20050222128-A1 | Compounds for the treatment of diseases | LTC4S, LTB4R2, CYP11B2 | AKR1B1 68/4885CYP1A2 71/4885CYP2C19 216/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | AKR1B1 90/4885CYP1A2 25/4885CYP2C19 163/4885 |
| US-20200165223-A1 | Diamide Compounds Having Muscarinic Receptor Antagonist and Beta2 Adrenergic Receptor Agonist Activity | ADRB2, ADRB1, ADRA2B | AKR1B1 334/4885CYP1A2 686/4885CYP2C19 1597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.